A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism

Archives of Internal Medicine

Volumn 160, Issue 13, 2000, Pages 2033-2041

  White, Richard H ^a,b   Zhou, Hong ^a   Kim, Jinwoo ^a   Romano, Patrick S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PSSB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; VEIN THROMBOSIS; VENA CAVA FILTER;

EID: 0034631989     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.13.2033     Document Type: Article

References (42)

1. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 1998;114(suppl):561S-578S.
2. Murphy TP, Trerotola SO, Vogelzang RL. Vena caval filters for the prevention of pulmonary embolism. N Engl J Med. 1998;339:46-48.
3. Ferris EJ, McCowan TC, Carver DK, McFarland DR. Percutaneous inferior vena caval filters: follow-up of seven designs in 320 patients. Radiology. 1993;188: 851-856.
4. Ortega M, Gahtan V, Roberts A, Matsumoto T, Kerstein M. Efficacy of anticoagulation post-inferior vena caval filter placement. Am Surg. 1998;64:419-423.
5. Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters: indications, safety, effectiveness. Arch Intern Med. 1992;152:1985-1994.
6. Dorfman GS. Percutaneous inferior vena caval filters. Radiology. 1990;174:987-992.
7. Greenfield LJ, Proctor MC. Twenty-year clinical experience with the Greenfield filter. Cardiovasc Surg. 1995;3:199-205.
8. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis: Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338:409-415.
9. Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998;339:93-104.
10. Arnold TE, Karabinis VD, Mehta V, Dupont EL, Matsumoto T, Kerstein MD. Potential of overuse of the inferior vena cava filter. Surg Gynecol Obstet. 1993;177: 463-467.
11. Alexander JJ, Yuhas JP, Piotrowski JJ. Is the increasing use of prophylactic percutaneous IVC filters justified? Am J Surg. 1994;168:102-106.
12. Meux EF, Stith SA, Zach A. Report of Results From the OSHPD Reabstracting Project: An Evaluation of the Reliability of Selected Patient Discharge Data, July Through December 1988. Sacramento, Calif: Office of Statewide Health Planning and Development; 1990.
13. White RH, Zhou H, Romano PS. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med. 1998;158:1005-1010.
14. Meux E. Encrypting personal identifiers. Health Serv Res. 1994;29:247-256.
15. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1988.
16. Kerr L. White Institute for Health Services Research. Anticoagulant management of venous thromboembolism: results of a multistate health care quality improvement program proiect [Colorado Foundation for Medical Care Web site]. Available at: http://www.cfmc.org/proj3.htm. Accessed May 1, 1999.
17. Crystal KS, Kase DJ, Scher LA, Shapiro MA, Naidich JB. Utilization patterns with inferior vena cava filters: surgical versus percutaneous placement. J Vasc Interv Radiol. 1995;6:443-448.
18. Katz MH, Hauck WW. Proportional hazards (Cox) regression. J Gen Intern Med. 1993;8:702-711.
19. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279: 458-462.
20. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med. 1998;128:737-740.
21. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
22. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995; 332:1661-1665.
23. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240-1245.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
25. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol 2. Lyon, France: International Agency for Research on Cancer; 1987.
26. Greenfield LJ, Michna BA. Twelve-year clinical experience with the Greenfield vena caval filter. Surgery. 1988;104:706-712.
27. Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery. 1991;109:12-15.
28. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985; 2:515-518.
29. Barritt D, Jordan S. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled clinical trial. Lancet. 1960;1:1309-1312.
30. Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-1489.
31. van den Belt AG, Sanson BJ, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med. 1997;157: 2227-2232.
32. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606-611.
33. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med. 1981;94:439-444.
34. Astermark J, Björgell O, Lindén E, Lethagen S, Nilsson P, Berntorp E. Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation. J Intern Med. 1998;244:79-82.
35. Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994;154:861-866.
36. Monreal M, Lafoz E, Ruiz J, Callejas JM, Arias A. Recurrent pulmonary embolism in patients treated because of acute venous thromboembolism: a prospective study. Eur J Vasc Surg. 1994;8:584-589.
37. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for afirst episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
38. Wittenberg G, Kueppers V, Tschammler A, Scheppach W, Kenn W, Hahn D. Long-term results of vena cava filters: experiences with the LGM and the Titanium Greenfield devices. Cardiovasc Intervent Radiol. 1998;21:225-229.
39. Piccioli A, Prandoni P, Goldhaber SZ. Epidemiologic characteristics, management, and outcome of deep venous thrombosis in a tertiary-care hospital: the Brigham and Women's Hospital DVT registry. Am Heart J. 1996;132:1010-1014.
40. Cohen JR, Grella L, Citron M. Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer. Cancer. 1992;70:1993-1996.
41. Golueke PJ, Garrett WV, Thompson JE, Smith BL, Talkington CM. Interruption of the vena cava by means of the Greenfield filter: expanding the indications, Surgery. 1988;103:111-117.
42. Pais SO, Mirvis SE, De Orchis DF. Percutaneous insertion of the Kimray-Greenfield filter: technical considerations and problems. Radiology, 1987;165: 377-381.